Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy
Monitoring the efficacy of antituberculosis therapy is crucial both for the individual patient and for better control of the spread of tuberculosis. We studied 18 patients with microbiologically confirmed tuberculosis, both at the time of diagnosis and 3 months after they started therapy, using an in vitro assay that detects T cell-mediated interferon- gamma response to selected peptides of Mycobacterium tuberculosis-specific early secretory antigenic target 6 (ESAT-6) protein. All patients had positive results at diagnosis; however, 3 months later, the response to ESAT-6 peptides was still detectable only in the 5 patients with microbiological isolation and/or absence of clinical improvement after treatment. On the basis of these data, we conclude that our assay is a useful tool in monitoring the efficacy of antituberculosis therapy.
| Errataetall: |
CommentIn: Clin Infect Dis. 2004 Mar 1;38(5):757-9. - PMID 14986263 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2004 |
|---|---|
| Erschienen: |
2004 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 38(2004), 5 vom: 01. März, Seite 754-6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carrara, Stefania [VerfasserIn] |
|---|
| Themen: |
Antigens, Bacterial |
|---|
| Anmerkungen: |
Date Completed 09.03.2004 Date Revised 15.11.2006 published: Print-Electronic CommentIn: Clin Infect Dis. 2004 Mar 1;38(5):757-9. - PMID 14986263 Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM146883128 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM146883128 | ||
| 003 | DE-627 | ||
| 005 | 20231223042148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2004 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0490.xml |
| 035 | |a (DE-627)NLM146883128 | ||
| 035 | |a (NLM)14986262 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carrara, Stefania |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy |
| 264 | 1 | |c 2004 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2004 | ||
| 500 | |a Date Revised 15.11.2006 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Infect Dis. 2004 Mar 1;38(5):757-9. - PMID 14986263 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Monitoring the efficacy of antituberculosis therapy is crucial both for the individual patient and for better control of the spread of tuberculosis. We studied 18 patients with microbiologically confirmed tuberculosis, both at the time of diagnosis and 3 months after they started therapy, using an in vitro assay that detects T cell-mediated interferon- gamma response to selected peptides of Mycobacterium tuberculosis-specific early secretory antigenic target 6 (ESAT-6) protein. All patients had positive results at diagnosis; however, 3 months later, the response to ESAT-6 peptides was still detectable only in the 5 patients with microbiological isolation and/or absence of clinical improvement after treatment. On the basis of these data, we conclude that our assay is a useful tool in monitoring the efficacy of antituberculosis therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antigens, Bacterial |2 NLM | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a ESAT-6 protein, Mycobacterium tuberculosis |2 NLM | |
| 700 | 1 | |a Vincenti, Donatella |e verfasserin |4 aut | |
| 700 | 1 | |a Petrosillo, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Amicosante, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Girardi, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Goletti, Delia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 38(2004), 5 vom: 01. März, Seite 754-6 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2004 |g number:5 |g day:01 |g month:03 |g pages:754-6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2004 |e 5 |b 01 |c 03 |h 754-6 | ||